As shown in Fig. 7H, I, high expression of ALDH1A1 or ZBTB7B in NSCLC patients treated with PD-1 blockade was associated with shortened progression-free survival (PFS). Here, ALDH1A1 is linked to non-small cell lung carcinoma.